Abstract CT158: Phase I study of ramucirumab, a recombinant human IgG1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, in Chinese patients with advanced solid tumors
Year: 2016
Type: conference-abstract
Source: Cancer Research
Institutions: Fudan University Shanghai Cancer Center, Lilly (China)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2497067009